



# First Indian patent approval for Episurf Medical

The Indian patent office Intellectual Property India has reported that Episurf Medical (NASDAQ: EPIS B) has received its first granted patent in India. The patent, entitled "*Surgical kit for cartilage repair comprising implant and a set of tools*", has a focus on Episurf Medical's individualised Episealer® Femoral Twin joint implant and its design process.

*"This patent forms a part of our global IP protection for the appreciated Episealer® Twin technology. This first approval in India comes very timely as we currently have commercial activities ongoing in the Indian market"*, comments Katarina Flodström, COO, Episurf Medical.

**For more information, please contact:**

Pål Ryfors, CEO, Episurf Medical  
Tel: +46 (0) 709 62 36 69  
Email: [p.al.ryfors@episurf.com](mailto:p.al.ryfors@episurf.com)

## About Episurf Medical

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).*

*This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 5 April 2022.*